Read previous post:
In combination with Gemzar, a nucleoside used in chemotherapy and marketed by Eli Lilly, eight of thirteen patients enrolled in a recent REOLYSIN study showed stability for twelve weeks or more.
Oncolytics Biotech’s REOLYSIN Inches Closer to Reality

The long and winding road. Investors know progress in biotech can be painfully slow. Oncolytics Biotech (TSX:ONC) can trace its...